W J Remme

Summary

Affiliation: Sticares Cardiovascular Research Foundation
Country: The Netherlands

Publications

  1. ncbi Public awareness of heart failure in Europe: first results from SHAPE
    Willem J Remme
    Sticares Cardiovascular Research Foundation, PO Box 882, 3160 AB Rhoon, The Netherlands
    Eur Heart J 26:2413-21. 2005
  2. ncbi Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET
    Willem J Remme
    Sticares Cardiovascular Research Institute, Rhoon, The Netherlands
    J Am Coll Cardiol 49:963-71. 2007
  3. ncbi Increasing awareness and perception of heart failure in Europe and improving care--rationale and design of the SHAPE Study
    Willem Remme
    Sticares Foundation, Rotterdam, The Netherlands
    Cardiovasc Drugs Ther 18:153-9. 2004
  4. ncbi Could beta-blockers precede or replace angiotensin-converting enzyme inhibitors in heart failure?
    Willem J Remme
    Sticares Cardiovascular Research Foundation, Rhoon, The Netherlands
    Heart Fail Clin 1:67-75. 2005
  5. ncbi The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN)
    Willem J Remme
    Sticares Cardiovascular Research Foundation, Rhoon, The Netherlands
    Cardiovasc Drugs Ther 18:57-66. 2004
  6. ncbi Pharmacological modulation of cardiovascular remodeling: a guide to heart failure therapy
    W J Remme
    Sticares Cardiovascular Research Foundation, Rhoon, The Netherlands
    Cardiovasc Drugs Ther 17:349-60. 2003
  7. ncbi Effect of carvedilol and metoprolol on the mode of death in patients with heart failure
    Willem J Remme
    Sticares Cardiovascular Research Foundation, PO Box 882, 3160 AB Rhoon, The Netherlands
    Eur J Heart Fail 9:1128-35. 2007
  8. ncbi Beta blockers or angiotensin-converting-enzyme inhibitor/angiotensin receptor blocker: what should be first?
    Willem J Remme
    Sticares Cardiovascular Research Institute, Rhoon, The Netherlands
    Cardiol Clin 25:581-94; vii. 2007
  9. ncbi Awareness and perception of heart failure among European cardiologists, internists, geriatricians, and primary care physicians
    Willem J Remme
    Sticares Cardiovascular Research Foundation, PO Box 882, 3160 AB Rhoon, The Netherlands
    Eur Heart J 29:1739-52. 2008
  10. ncbi Secondary prevention of coronary disease with ACE inhibition--does blood pressure reduction with perindopril explain the benefits in EUROPA?
    Willem J Remme
    Sticares Cardiovascular Research Institute, Rhoon, The Netherlands
    Cardiovasc Drugs Ther 23:161-70. 2009

Detail Information

Publications38

  1. ncbi Public awareness of heart failure in Europe: first results from SHAPE
    Willem J Remme
    Sticares Cardiovascular Research Foundation, PO Box 882, 3160 AB Rhoon, The Netherlands
    Eur Heart J 26:2413-21. 2005
    ..The extent of public awareness in Europe is not known...
  2. ncbi Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET
    Willem J Remme
    Sticares Cardiovascular Research Institute, Rhoon, The Netherlands
    J Am Coll Cardiol 49:963-71. 2007
    ..We explored whether vascular protection by carvedilol could contribute to its superior effects in the treatment of heart failure (HF) compared with metoprolol tartrate in the COMET (Carvedilol Or Metoprolol European Trial) study...
  3. ncbi Increasing awareness and perception of heart failure in Europe and improving care--rationale and design of the SHAPE Study
    Willem Remme
    Sticares Foundation, Rotterdam, The Netherlands
    Cardiovasc Drugs Ther 18:153-9. 2004
    ....
  4. ncbi Could beta-blockers precede or replace angiotensin-converting enzyme inhibitors in heart failure?
    Willem J Remme
    Sticares Cardiovascular Research Foundation, Rhoon, The Netherlands
    Heart Fail Clin 1:67-75. 2005
  5. ncbi The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN)
    Willem J Remme
    Sticares Cardiovascular Research Foundation, Rhoon, The Netherlands
    Cardiovasc Drugs Ther 18:57-66. 2004
    ..CARMEN explored the need for combined treatment for remodelling and order of introduction by comparing the ACE-I enalapril against carvedilol and their combination...
  6. ncbi Pharmacological modulation of cardiovascular remodeling: a guide to heart failure therapy
    W J Remme
    Sticares Cardiovascular Research Foundation, Rhoon, The Netherlands
    Cardiovasc Drugs Ther 17:349-60. 2003
    ..Whereas insight in cardiovascular remodeling has already significantly contributed to existing management strategies in heart failure, further studies in different mechanisms may provide additional therapeutic measures...
  7. ncbi Effect of carvedilol and metoprolol on the mode of death in patients with heart failure
    Willem J Remme
    Sticares Cardiovascular Research Foundation, PO Box 882, 3160 AB Rhoon, The Netherlands
    Eur J Heart Fail 9:1128-35. 2007
    ..In the COMET study, carvedilol improved survival compared to metoprolol tartrate in 3029 patients with NYHA II-IV heart failure and EF <35%, followed for an average of 58 months...
  8. ncbi Beta blockers or angiotensin-converting-enzyme inhibitor/angiotensin receptor blocker: what should be first?
    Willem J Remme
    Sticares Cardiovascular Research Institute, Rhoon, The Netherlands
    Cardiol Clin 25:581-94; vii. 2007
    ..However, early combined treatment with both neurohormonal antagonists remains preferable to either neurohormonal antagonist alone and should not be delayed...
  9. ncbi Awareness and perception of heart failure among European cardiologists, internists, geriatricians, and primary care physicians
    Willem J Remme
    Sticares Cardiovascular Research Foundation, PO Box 882, 3160 AB Rhoon, The Netherlands
    Eur Heart J 29:1739-52. 2008
    ..To assess awareness of heart failure (HF) management recommendations in Europe among cardiologists (C), internists and geriatricians (I/G), and primary care physicians (PCPs)...
  10. ncbi Secondary prevention of coronary disease with ACE inhibition--does blood pressure reduction with perindopril explain the benefits in EUROPA?
    Willem J Remme
    Sticares Cardiovascular Research Institute, Rhoon, The Netherlands
    Cardiovasc Drugs Ther 23:161-70. 2009
    ..We determined whether blood pressure (BP) lowering by perindopril was related to its benefit in the EUROPA study...
  11. ncbi Comprehensive guidelines for the diagnosis and treatment of chronic heart failure. Task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology
    Willem J Remme
    Sticares, Cardiovascular Research Foundation, P.O. Box 882, 3160 AB, Rhoon, The Netherlands
    Eur J Heart Fail 4:11-22. 2002
  12. ncbi The rationale and design of the PERindopril GENEtic association study (PERGENE): a pharmacogenetic analysis of angiotensin-converting enzyme inhibitor therapy in patients with stable coronary artery disease
    J J Brugts
    Department of Cardiology, Erasmus Medical Center, Rotterdam, The Netherlands
    Cardiovasc Drugs Ther 23:171-81. 2009
    ..Until now, pharmacogenetic research of the efficacy of ACE-inhibitor therapy in CAD patients is still in a preliminary stage...
  13. ncbi Congestive heart failure. Drug therapy: central or peripheral approach?
    W J Remme
    Sticares, Cardiovascular Research Foundation, Rotterdam, The Netherlands
    Cardiologia 38:51-9. 1993
    ..This may be different where compounds which act through cAMP-independent mechanisms, i.e., calcium sensitization or sodium channel stimulation, are concerned, but needs to be confirmed yet.(ABSTRACT TRUNCATED AT 250 WORDS)..
  14. ncbi Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk
    Jaap W Deckers
    Department of Cardiology, Thoraxcenter, Erasmus University Medical Center Rotterdam, The Netherlands
    Eur Heart J 27:796-801. 2006
    ..We developed a cardiovascular risk model based on the EUROPA study population and investigated whether benefit of long-term administration of the angiotensin-converting enzyme (ACE)-inhibitor perindopril was modified by risk level...
  15. ncbi PERindopril-Function of the Endothelium in Coronary Artery Disease Trial: the PERFECT study--sub study of EUROPA: rationale and design
    Michiel L Bots
    Julius Center for Health Sciences and Primary Care, HP D01 335, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands
    Cardiovasc Drugs Ther 16:227-36. 2002
    ..The PERFECT study was designed to verify the above mentioned pathophysiological concepts...
  16. ncbi A description of the clinical characteristics at baseline of patients recruited into the Carvedilol or Metoprolol European Trial (COMET)
    John G F Cleland
    University of Hull, Kingston upon Hull, UK
    Cardiovasc Drugs Ther 18:139-52. 2004
    ..The purpose of this report is to describe in greater detail the heterogeneity of this population at baseline with particular reference to the impact of symptomatic severity, age and gender on patient characteristics...
  17. ncbi Should beta-blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET
    Marco Metra
    Section of Cardiovascular Diseases, Department of Experimental and Applied Medicine, University of Brescia, Italy
    Eur J Heart Fail 9:901-9. 2007
    ..We studied the relationship between changes in beta-blocker dose and outcome in patients surviving a HF hospitalisation in COMET...
  18. ncbi Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a beta-blocker: results from the Carvedilol Or Metoprolol European Trial (COMET) trial
    Lars G Olsson
    Department of Emergency and Cardiovascular Medicine Sahlgrenska Academy, Goteborg University, Goteborg, Sweden, and Department of Cardiology, La Pitie Salpetriere Hospital, Paris, France
    Eur J Heart Fail 9:795-801. 2007
    ..Beta-blockers (BB) may influence these levels but it is unclear whether changes in NT-pro BNP reflect concomitant changes in prognosis...
  19. ncbi Should ACE inhibition always be first-line therapy in heart failure? Lessons from the CARMEN Study
    Willem J Remme
    Cardiovasc Drugs Ther 17:107-9. 2003
  20. ncbi Filling the gap between guidelines and clinical practice in heart failure treatment: still a far cry from reality
    Willem J Remme
    Eur J Heart Fail 9:1143-5. 2007
  21. ncbi Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial
    Philip A Poole-Wilson
    National Heart and Lung Institute, Imperial College, London, UK
    Lancet 362:7-13. 2003
    ..We aimed to compare the effects of carvedilol and metoprolol on clinical outcome...
  22. ncbi Insight into ACE inhibition in the prevention of cardiac events in stable coronary artery disease: the EUROPA trial
    Roberto Ferrari
    Chair of Cardiology, University of Ferrara, Arcispedale S Anna, Corso Giovecca 203, 44100, Ferrara, Italy
    Expert Rev Cardiovasc Ther 5:1037-46. 2007
    ..Data on the pathophysiological mechanisms underlying CAD indicate direct vascular protection with perindopril. This helps explain why perindopril is beneficial in preventing cardiac events in stable CAD patients...
  23. ncbi Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN)
    Michel Komajda
    Institut de Cardiologie, Centre Hospitalier GH Pitié Salpêtrière, 47 83 bld de l Hôpital, 75013, Paris Cedex 13, France
    Eur J Heart Fail 6:467-75. 2004
    ..Management guidelines for heart failure recommend ACE-I and beta-blockers. The perception of difficult up-titration might have added to the slow uptake of beta-blockers despite their mortality and morbidity benefits...
  24. ncbi Effects of perindopril on long-term clinical outcome of patients with coronary artery disease and preserved left ventricular function
    Michel E Bertrand
    Lille Heart Institute, Lille, France
    Int J Cardiol 121:57-61. 2007
    ..The EUROPA trial has demonstrated that an ACE inhibitor perindopril, was able to significantly decrease the risk of major cardiac events in patients with stable coronary heart disease without apparent heart failure...
  25. ncbi Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET)
    Christian Torp-Pedersen
    Department of Cardiology, Bispebjerg University Hospital, Copenhagen NV, Denmark
    Heart 93:968-73. 2007
    ..Beta blocker treatment may worsen glucose metabolism...
  26. ncbi Exchange of beta-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial)
    Andrea Di Lenarda
    Department of Cardiology, Ospedale di Cattinara, Strada di Fiume 447, 34100 Trieste, Italy
    Eur J Heart Fail 7:640-9. 2005
    ..metoprolol tartrate, a beta1-selective blocker, in patients with mild-to-severe chronic heart failure (CHF). Patients on treatment with metoprolol might benefit from switching to carvedilol...
  27. ncbi Do standardized beta-blocker titration protocols in heart failure improve compliance? The GESICA registry experience
    Willem J Remme
    Cardiovasc Drugs Ther 19:99-101. 2005
  28. ncbi Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial
    Marco Metra
    Cattedra di Cardiologia, Universita di Brescia, Italy
    Eur Heart J 26:2259-68. 2005
    ....
  29. ncbi The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy
    Caroline A Daly
    Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK
    Eur Heart J 26:1369-78. 2005
    ....
  30. ncbi Economic evaluation of the randomized aldactone evaluation study (RALES): treatment of patients with severe heart failure
    Henry A Glick
    Division of General Internal Medicine and the Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia 19104, USA
    Cardiovasc Drugs Ther 16:53-9. 2002
    ..To use data from the Randomized Aldactone Evaluation Study (RALES) to compare clinical outcomes and costs as part of the assessment of the economic implications of spironolactone treatment of advanced heart failure...
  31. ncbi Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure--COMET
    Christian Torp-Pedersen
    Department of Cardiology, Bispebjerg University Hospital, Copenhagen, Denmark
    Am Heart J 149:370-6. 2005
    ..Beta-blockers with different receptor bindings reduce mortality in patients with chronic heart failure. We compared the effects of the beta1-blocker metoprolol tartrate and the beta1-, beta2-, and alpha1-blocker carvedilol...
  32. ncbi A comparison of the effects of carvedilol and metoprolol on well-being, morbidity, and mortality (the "patient journey") in patients with heart failure: a report from the Carvedilol Or Metoprolol European Trial (COMET)
    John G F Cleland
    Department of Cardiology, University of Hull, Kingston upon Hull, United Kingdom
    J Am Coll Cardiol 47:1603-11. 2006
    ..This study was designed to investigate the loss of well-being, in terms of life-years, overall and in patients randomized to metoprolol versus carvedilol in the Carvedilol Or Metoprolol European Trial (COMET)...
  33. ncbi Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study
    Andrew Briggs
    Public Health and Health Policy, University of Glasgow, Glasgow, UK
    Heart 93:1081-6. 2007
    ..The EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) trial has recently reported...
  34. ncbi The cardioprotective effects of the angiotensin-converting enzyme inhibitor perindopril in patients with stable coronary artery disease are not modified by mild to moderate renal insufficiency: insights from the EUROPA trial
    Jasper J Brugts
    Department of Cardiology, Thoraxcenter Erasmus Medical Center, Rotterdam, The Netherlands
    J Am Coll Cardiol 50:2148-55. 2007
    ..This study sought to examine whether the cardioprotective effects of angiotensin-converting enzyme (ACE) inhibitor therapy by perindopril are modified by renal function in patients with stable coronary artery disease...
  35. ncbi Secondary prevention of coronary artery disease and the choice of the ACE inhibitor why EUROPA and not PEACE
    Willem J Remme
    Cardiovasc Drugs Ther 21:405-7. 2007
  36. ncbi Efficacy of perindopril in reducing risk of cardiac events in patients with revascularized coronary artery disease
    Kim M Fox
    Cardiology Department, Royal Brompton Hospital, Sydney Street, London, UK
    Am Heart J 153:629-35. 2007
    ....
  37. ncbi [Guidelines for the Diagnosis and Treatment of Chronic Heart Failure: executive summary (update 2005)]
    Karl Swedberg
    Sahlgrenska Academy, , , Sweden
    Rev Esp Cardiol 58:1062-92. 2005
  38. ncbi Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology
    Karl Swedberg
    , Department of Medicine, Sahlgrenska University Hospital, Sweden
    Eur Heart J 26:1115-40. 2005